Risk sharing agreements

Panos Kanavos
Warsaw, 26 September 2014
Advance-HTA Capacity building workshop
Background

- Increasing cost of new medicines
- Presence of a significant degree of uncertainty at the time of making coverage decisions
- Need for innovative solutions to make new drugs available to patients while ensuring the long-term financial sustainability of healthcare systems
Constructing RSAs – Key sources of uncertainty

- **Uncertainty around clinical evidence**
  - More robust clinical evidence is needed about who is likely to benefit most

- **Uncertainty around cost-effectiveness**
  - Average cost-effectiveness is higher than country’s WTP

- **Uncertainty around budget impact**
  - Budget impact is too high if all potentially eligible patients are treated

- **Uncertainty around price**
  - Not clear how pricing strategy results in a price that is significantly higher than BAT

- **Uncertainty around eligible patient population**
  - Not clear who is likely to benefit most
  - Not clear how many patients exist in this indication
Risk Sharing and Managed Entry Agreements

WHY?

• Uncertainty around clinical evidence
  • More robust clinical evidence is needed about who is likely to benefit most

• Uncertainty around cost-effectiveness
  • Average cost-effectiveness is higher than country’s WTP

• Uncertainty around budget impact
  • Budget impact is too high if all potentially eligible patients are treated

• Uncertainty around price
  • Not clear how pricing strategy results in a price that is significantly higher than BAT

• Uncertainty around eligible patient population
  • Not clear who is likely to benefit most
  • Not clear how many patients exist in this indication

Financial

Outcomes-related

Combination of both
Payer option flow diagram

Payer options

- Payer adopts: no new evidence required (YES)
  - Manufacturer has option to reapply with more evidence
    - Use only in research

- Payer refuses to adopt (NO)

- Payer adopts with additional evidence (CED) (YES BUT)
  - CED with negotiation. No pre-specified agreement
  - CED linked to performance agreement

- Outcomes based
  - Utilization uncertainty

- Non-outcomes based
  - Budget cap
  - Price discount
Coverage with Evidence Development

• Product is covered or reimbursed when used under controlled circumstances:
  – RCTs
  – Utilisation Management Schemes (UMS)
  – Evidence-providing Registries

• Examples
  – Coverage of CRC agent by Medicare via RCT and UMS
  – Coverage of prostate cancer “vaccine” by Medicare via building evidence-providing registry
Conditional Coverage

• Price and reimbursement are (temporary) granted but failure to achieve set targets can result in price and reimbursement changes and/or rebates

• Examples
  – Pfizer on statins in the UK
  – UK NICE MS scheme
  – France: Acomplia
Outcome Guarantee

• Rebates or free product are given by the manufacturer when outcomes are not achieved for individual patients
• Presupposes ability to monitor eligible patients well
• Example: Bortezomib case in UK through NICE guidance (case study separately)
Price and Volume (Budget) Agreements

• A penalty is foreseen when a new drug is overshooting a pre-set budget (PxQ)
• Penalty can take the form of
  – Rebate or payback
  – Lower price for volume above agreed limit
  – Lower future price
• Variety of payback clauses
  – Supplier is fully accountable
  – Prescriber and supplier are jointly accountable
  – Rebate/Payback to be shared among suppliers
• Examples: Australia, France, Italy, Austria, Portugal
<table>
<thead>
<tr>
<th>Risk Addressed</th>
<th>Right patients</th>
<th>Uncertain clinical value</th>
<th>Low cost effectiveness</th>
<th>Budget overspend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage with ED</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>x</td>
</tr>
<tr>
<td>Conditional coverage</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Outcome guarantee</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>x</td>
</tr>
<tr>
<td>Price-volume deal</td>
<td>x</td>
<td>x</td>
<td>X</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Main objectives of MEAs

BI: Budget impact
CE: Cost-effectiveness

Source: Ferrario & Kanavos, 2013
Common elements of MEAs

PVAs: Price-volume agreements
pp: per person

Source: Ferrario & Kanavos, 2013
**Therapeutic classes**

ATC groups (according to ATC-index 2011)
A: Alimentary tract and metabolism
B: Blood and blood forming organs
C: Cardiovascular system
D: Dermatologicals
G: Genito urinary system and sex hormones
H: Systemic hormonal preparations, excl. sex hormones and insulins
J: Anti-infectives for systemic use
L: Antineoplastic and immuno-modulating agents
M: Musculo-skeletal system
N: Nervous system
R: Respiratory system
S: Sensory organs;
V: Various

ATC_Mix: There was one case in Italy where a particular AIFA-note contained medicines from different ATC-groups.

Source: Ferrario & Kanavos, 2013
Duration

- The average duration of MEAs varies between Member States, ranging from one year in Belgium (renewable) to up to four years in the Netherlands or for an indefinite period of time subject to review (France, Malta, UK).
# Main instruments linked to MEAs

<table>
<thead>
<tr>
<th>Examples of instruments used</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales and expenditure databases</td>
<td><strong>198</strong></td>
</tr>
<tr>
<td></td>
<td>- Italy: 85</td>
</tr>
<tr>
<td></td>
<td>- Portugal: 76</td>
</tr>
<tr>
<td></td>
<td>- Lithuania: 35</td>
</tr>
<tr>
<td></td>
<td>- Sweden 2</td>
</tr>
<tr>
<td>Patient registries</td>
<td><strong>119</strong></td>
</tr>
<tr>
<td></td>
<td>- Italy: 78</td>
</tr>
<tr>
<td></td>
<td>- Czech Republic: 21</td>
</tr>
<tr>
<td></td>
<td>- Belgium: 13</td>
</tr>
<tr>
<td></td>
<td>- Sweden: 7</td>
</tr>
<tr>
<td>Studies</td>
<td><strong>64</strong></td>
</tr>
<tr>
<td>Online systems for reimbursement</td>
<td><strong>11</strong></td>
</tr>
<tr>
<td></td>
<td>- UK: 11</td>
</tr>
</tbody>
</table>
Actors involved in implementing MEAs

- Main stakeholders involved
  - Payers, drug assessment agencies, and physicians
- Responsibility for negotiating the agreement with the manufacturer
  - Payers (e.g. NIHDI in Belgium), drug assessment agencies (e.g. AIFA in Italy, TLV in Sweden) or DoH (UK)
- Responsibility for filling in the patient registries
  - Physicians usually in collaboration with other stakeholders (e.g. monitoring registries in Italy are managed by AIFA; an advisor physician from the National Health Insurer controls the implementation of MEAs in Belgium)
- Responsibility for data provision
  - Manufacturers
Taxonomy: A framework for analysing and evaluating MEAs
Managed entry schemes

**Objective**

**Financial schemes**
- Total cost for all patients
- Total cost per patient

**Performance-based agreements**
- Utilisation in the real life
- Evidence regarding decision uncertainty

**Monitoring**
- Discounts
- Price/volume
- Utilisation capping

**Combination of financial and performance elements**

**Instruments**
- Performance based reimbursement
- Coverage with evidence development

**Impact**
- Initial discount on all doses or free initial doses for eligible patients
- Discount or free doses after the agreed spending/volume threshold is reached
- Reimbursement for higher than forecasted expenditure
- Cap on number of doses/total cost reimbursed per patient after which the manufacturer assumes the cost

- Reimbursement if drug is not effective
- Treatment interruption if drug is not effective according to pre-established targets
- Discount if drug is not effective or less effective than expected
- Reassessment which may lead to price change, conclusion of new agreements, or new reimbursement decision

- Outcome guarantees
- Patient eligibility with conditional treatment continuation
A strong Value Proposition will be payer-centric in nature, and will contain compelling evidence that

- Showcases all dimensions of value (medical/therapeutic-, patient reported outcome- and economic benefits)
- Reflects the full impact of the innovation to payers and HTAs and
- Translates the clinical profile into a compelling cost/effectiveness ratio

- Using comprehensive and good quality evidence

- Leveraging critical value dimensions with a view to constructing *tailor-made RSA plans*
Payer-centric Value Proposition (1)

• Critical elements that payers may require include:

  – **Differentiation relative to standard of care**
    Although superiority might be shown against BSC on all primary- and secondary endpoints, it may deter payers from considering the improvement as being major

  – **Relevant comparator (head-to-head)**
    A placebo-controlled trial is often seen as a weakness. Payers prefer to see H2H trials. In the absence of H2H data, payers would need to see data for detailed indirect comparison across the primary and secondary endpoints that incorporate any difference in trials.
Payer-centric Value Proposition (2)

– **Quality of evidence**
The non-significant claim on overall survival will negatively impact the value perception for payers. Without a clear statistical superiority claim for overall survival, payers will consider new therapies at most comparable to existing ones despite new therapies showing considerable additional benefits on other attributes.

– **Data collection**
If time horizon is not long enough to capture full clinical- and economic impact of disease payers may demand long-term (real life) data.

– **Comparative efficacy/effectiveness**
Measures of effect in “real-life” conditions: Clinical- and cost effectiveness data in real-world vs. a clinical setting.

– **Cost effectiveness data**
Evidence used for the NICE submission but possible other additional
Additional evidence requirements

• Payers may require additional data besides the pivotal trial results through follow up studies or registries in order to reduce uncertainties including
  
• Collect H2H comparative data that demonstrate better any treatment differences
  
• Provide data that reflect (more) statistically significant outcomes (e.g. in OS or PFS)
  
• Address uncertainties in clinical-and cost effectiveness in real world (e.g. PRO metrics)
  
• Collect real world (effectiveness) data
Value is multi-dimensional...
...a practical and necessary set of dimensions should be considered

<table>
<thead>
<tr>
<th>Efficacy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct endpoints</td>
<td></td>
</tr>
<tr>
<td>Survival</td>
<td></td>
</tr>
<tr>
<td>Disease progression</td>
<td></td>
</tr>
<tr>
<td>Disease recovery</td>
<td></td>
</tr>
<tr>
<td>Clinical events</td>
<td></td>
</tr>
<tr>
<td>Symptoms scores</td>
<td></td>
</tr>
<tr>
<td>HRQoL</td>
<td></td>
</tr>
<tr>
<td>Indirect endpoints</td>
<td></td>
</tr>
<tr>
<td>Validated endpoints</td>
<td></td>
</tr>
<tr>
<td>Non-validated endpoints</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Safety</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse drug events</td>
<td></td>
</tr>
<tr>
<td>Tolerability</td>
<td></td>
</tr>
<tr>
<td>Contraindications and special warnings</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Innovation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism of Action (MoA)</td>
<td></td>
</tr>
<tr>
<td>Patient convenience</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Socioeconomic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Public health</td>
<td></td>
</tr>
<tr>
<td>Direct costs</td>
<td></td>
</tr>
<tr>
<td>Indirect costs</td>
<td></td>
</tr>
</tbody>
</table>
## Comparative presentation of value drivers

<table>
<thead>
<tr>
<th>Value drivers</th>
<th>GRECOTINIB vs. HELLASOMAB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Inferior</td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
</tr>
<tr>
<td>Overall Survival (OS)</td>
<td>Median</td>
</tr>
<tr>
<td>Overall Survival (OS)</td>
<td>Mean</td>
</tr>
<tr>
<td>Skeletal Related Effects (SRE)</td>
<td>Time to first</td>
</tr>
<tr>
<td>Skeletal Related Effects (SRE)</td>
<td>Incidence</td>
</tr>
<tr>
<td>Objective Response Rate (ORR)</td>
<td></td>
</tr>
<tr>
<td>Radiographic Progression Free Survival (rPFS)</td>
<td>Median time to</td>
</tr>
<tr>
<td>Modified Progression Free Survival (mPFS)</td>
<td>Median time to</td>
</tr>
<tr>
<td><strong>Biomarker Response</strong></td>
<td></td>
</tr>
<tr>
<td>Time to treatment discontinuation (TTTD)</td>
<td>Patients proportion</td>
</tr>
<tr>
<td>Radiographic Progression Free Survival (rPFS)</td>
<td>Patient proportion free of progression</td>
</tr>
<tr>
<td>Biomarker Progression</td>
<td>Patient proportion free of progression</td>
</tr>
<tr>
<td>Skeletal Related Effects (SRE)</td>
<td>Rate</td>
</tr>
<tr>
<td>Biomarker Progression</td>
<td>Median time to</td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>Hypokalemia</td>
</tr>
<tr>
<td>Tolerability</td>
<td>Hepatotoxicity</td>
</tr>
<tr>
<td>Adverse events</td>
<td>Bone pain</td>
</tr>
<tr>
<td><strong>Innovation</strong></td>
<td></td>
</tr>
<tr>
<td>Mechanism of Action (MoA)</td>
<td></td>
</tr>
<tr>
<td>Patient convenience</td>
<td>Special instructions</td>
</tr>
<tr>
<td><strong>Socioeconomic</strong></td>
<td></td>
</tr>
<tr>
<td>Direct medical costs</td>
<td>Outpatient visits</td>
</tr>
<tr>
<td>Value for money</td>
<td>Cost effectiveness</td>
</tr>
<tr>
<td>Value for money</td>
<td>Cost minimisation</td>
</tr>
</tbody>
</table>
Health Insurers might be willing to confirm the content of the Value Proposition or willing to build their own version reflecting or adjusting for their own perspective.

- Most of the data should be available through the peer review literature
  - If not published their credibility might be questioned
  - Insurers might conduct their own systematic literature review(s) to ensure all critical evidence is incorporated

- Other sources might be required for the collection of real world effectiveness data and resource use (cost of illness) data
  - Registries and observational studies
Constructing RSAs

- The content of the value proposition can then inform the discussions surrounding the development of potential RSA options.

- Aim is to leverage Uncertainties (clinical, cost-effectiveness, other) of the technology in order to decrease the risk of a worst-off clinical benefit-risk ratio (BRR) or incremental cost effectiveness ratio (ICER) in real settings.

- Need to make a series of hypothetical scenarios on expected volumes and expected prices.
Volume expectations

- Expectations on volume are needed to inform RSAs.

- Follow-on products: epidemiological data on disease prevalence should be available
  - WHO, CDC, national databases, peer review literature

- First-in-class: data on disease prevalence might not be available
  - Conduct primary data collection activities such as observational and descriptive studies, e.g. national registries
Choose clinically meaningful endpoints that are
- Objective
- Patient/disease relevant
- Operational (i.e. practical and measurable)
- “Cheap” to monitor
- Can be monitored within a specified amount of time

Potential endpoints include biomarker response to treatment (i.e. response rate), biomarker progression following treatment (i.e. disease progression), radiographic exams, etc.
Financial based RSAs

- Simpler than performance based agreements
- Make use of confidential discounts between the manufacturer and the payer
- Sales cap based on price-volume agreement
- Based on the grounds of budget impact

- Potential options include the application of single discounts, multiple discounts (e.g. 100% discount for the first 3 mo, 50% discount for the next 3 mo, ending up paying full price), and revenue or sales caps